These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 19645340)

  • 21. An audience with... Joanna F. Haas.
    Haas JF
    Nat Rev Drug Discov; 2005 Oct; 4(10):806. PubMed ID: 16237844
    [No Abstract]   [Full Text] [Related]  

  • 22. European perspective on risk management and drug safety.
    Raine J; Wise L; Blackburn S; Eichler HG; Breckenridge A
    Clin Pharmacol Ther; 2011 May; 89(5):650-4. PubMed ID: 21512526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Erice Manifesto: for global reform of the safety of medicines in patient care.
    Drug Saf; 2007; 30(3):187-90. PubMed ID: 17343426
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacovigilance activities in the United States, European Union and Japan: harmonic convergence or convergent evolution?
    Faden LB; Milne CP
    Food Drug Law J; 2008; 63(3):683-700. PubMed ID: 19031668
    [No Abstract]   [Full Text] [Related]  

  • 27. The dilemma of reporting device-related adverse events.
    Donawa M
    Med Device Technol; 2003; 14(1):26-31. PubMed ID: 12974122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The precautionary principle and pharmaceutical risk management.
    Callréus T
    Drug Saf; 2005; 28(6):465-71. PubMed ID: 15924501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulatory innovation in postmarketing risk assessment and management.
    Staffa JA; Dal Pan GJ
    Clin Pharmacol Ther; 2012 Mar; 91(3):555-7. PubMed ID: 22297386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Food and Drug Administration Amendments Act of 2007: drug safety and health-system pharmacy implications.
    Meyer BM
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S3-5. PubMed ID: 19966078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA seeks advice on track-and-trace systems.
    Traynor K
    Am J Health Syst Pharm; 2011 Apr; 68(7):552-4. PubMed ID: 21411794
    [No Abstract]   [Full Text] [Related]  

  • 32. IOM panel hears concerns about U.S. drug safety system.
    Young D
    Am J Health Syst Pharm; 2005 Jul; 62(14):1428, 1430-31. PubMed ID: 15998915
    [No Abstract]   [Full Text] [Related]  

  • 33. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving paradigms in pharmacovigilance.
    Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
    Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quality, safety and efficacy of follow-on biologics in Japan.
    Yamaguchi T; Arato T
    Biologicals; 2011 Sep; 39(5):328-32. PubMed ID: 21890377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post Launch Monitoring of food products: what can be learned from pharmacovigilance.
    van Puijenbroek EP; Hepburn PA; Herd TM; van Grootheest AC
    Regul Toxicol Pharmacol; 2007 Mar; 47(2):213-20. PubMed ID: 17204356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic risk management interventions: feasibility and effectiveness.
    Andrews E; Gilsenan A; Cook S
    J Am Pharm Assoc (2003); 2004; 44(4):491-500. PubMed ID: 15372870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The new pharmacovigilance legislation in practice].
    Broekmans AW; Mol PG
    Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.